Replies to post #54964 on NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

I have dropped hints to others and will reiterate to you that you should learn as much as you can about CXCR4. --- Doc logic

I thought that NWBO might have sold their rights/patents regarding CXCR4, but then I came across this:
http://www.sec.gov/Archives/edgar/data/1072379/000089102002001976/v86458exv99w1.txt
includes:

NORTHWEST BIOTHERAPEUTICS' DEAL PROVIDES FUNDING AND PRODUCT RIGHTS TO CANCER
TARGETS

BOTHELL, WASHINGTON, - DECEMBER 11, 2002 - NORTHWEST BIOTHERAPEUTICS, INC.
(Nasdaq: NWBT) today announced that it has signed an agreement with Medarex Inc.
(Nasdaq: MEDX) providing Northwest Biotherapeutics, Inc. (NWBio) with $3 million
in funding; potential future royalties; and, certain diagnostic rights for two
of the three cancer-related disease targets being acquired by Medarex. These
targets were previously co-owned by the companies. This agreement also provides
Medarex with the assignment of certain patents related to the acquired targets
for the development and commercialization of antibody-based products including
fully human anti-PSMA (prostate specific membrane antigen) antibodies for the
potential treatment of prostate cancer.

In addition, the agreement provides for NWBio to reacquire all development and
commercialization rights it had previously granted to Medarex to five potential
additional cancer-related disease targets. One of these targets is CXCR4, a
potential antibody, anti-sense and small molecule target found in preclinical
evaluations to be over expressed in multiple cancers and to be involved in tumor
growth and metastasis. Medarex will receive 2,000,000 shares of NWBio common
stock and warrants to purchase an additional 800,000 NWBio shares at market
value for these rights.

"This deal represents a major milestone in our efforts to reposition NWBio for
the future. It provides funding for the coming year and returns important
technology rights for the implementation of our revised and streamlined
strategic initiatives," said Daniel O. Wilds, President and Chief Executive
Officer of NWBio.

Dr. Alton L. Boynton, Chief Operating and Scientific Officer, and one of NWBio's
founders commented, "The scientific and potential commercial and medical
importance of the targets being reacquired by NWBio is just beginning to be
recognized. One of our strategic initiatives for 2003 will be to further
establish the value of these targets and to position them for future clinical
trials."